Credit Suisse Ag Aptevo Therapeutics Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$6.21 - $48.36 $336,383 - $2.62 Million
-54,168 Closed
0 $0
Q3 2020

Nov 13, 2020
BUY
$7.21 - $9.37 $390,551 - $507,554
54,168 New
54,168 $412,000

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $24.5M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email